SEC Form 4 · accession 0001209191-18-062943
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edmund Harrigan
Director
Period of report
Dec 13, 2018
Accepted (ET)
Dec 17, 2018 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.65 | Dec 13, 2018 | A | 68,966 | A | — | Dec 13, 2028 | Common Stock | 68,966 | 68,966 | D |
Explanation of responses
- F1The shares subject to the option shall vest in equal monthly installments over 36 months on the same day of the month as the Initial Vesting Date, subject to the reporting person's continued service through each such date.